M. Pancera

Broadly inhibitory antibodies against severe malaria virulence proteins

The paper identifies two human monoclonal antibodies that broadly inhibit PfEMP1's binding to EPCR, a key process in severe malaria pathogenesis.

Structural basis of epitope selectivity and potent protection from malaria by PfCSP antibody L9

The paper determines the cryo-EM structure of the anti-PfCSP antibody L9, revealing its multivalent binding to NPNV repeats and the role of the light chain in affinity and protective efficacy.

Cross-Protective Antibodies Against Common Endemic Respiratory Viruses

This study identifies two cross-neutralizing monoclonal antibodies targeting multiple respiratory viruses and validates their efficacy through structural and functional analyses.

Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge

This study evaluates a nanoparticle vaccine displaying EBV gH/gL, showing it protects humanized mice against lethal EBV challenge, while monomeric gH/gL does not.

Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain

The paper identifies an antibody from a clinical trial that binds a different HIV-1 Env domain than VRC01-class antibodies and shows that epitope switching requires specific CDR changes.

The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malaria

This study shows that the L9 antibody's light chain is essential for binding PfCSP minor repeats and enhancing neutralization of malaria sporozoites.

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit.

This paper identifies a conserved neutralizing epitope on the spike S2 subunit of sarbecoviruses, demonstrating cross-neutralization against multiple variants and a bat coronavirus.

Structurally related but genetically unrelated antibody lineages converge on an immunodominantHIV-1 Env neutralizing determinant following trimer immunization

The paper analyzes monoclonal antibodies from vaccinated non-human primates to identify a conserved immunodominant epitope in HIV-1 Env and how different lineages target it for potent neutralization.

Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects

The paper isolates and characterizes cross-neutralizing antibodies from COVID-19 patients, identifying antibodies that neutralize both SARS-CoV-1 and SARS-CoV-2, including variants.

Antibody binding to SARS-CoV-2 S glycoprotein correlates with, but does not predict neutralization

Protective Antibodies Against Human Parainfluenza Virus Type 3 (HPIV3) Infection

The paper identifies a monoclonal antibody, PI3-E12, that neutralizes HPIV3 and provides protection in cotton rats, showing potential for clinical use in both immunocompetent and immunocompromised individuals.

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

The paper determines the X-ray crystal structure of a potent SARS-CoV-2 neutralizing antibody, CV30, in complex with the RBD, showing its epitope overlaps with ACE2 binding site.

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual

This study characterizes neutralizing antibodies from a SARS-CoV-2 infected individual, finding that most antibodies are non-neutralizing and target epitopes outside the RBD, while two potent neutralizers bind the RBD with minimal mutation.